Drug intelligence / Profile preview

Eryfotona AK-NMSC

Development stage: Unknown
Lead developer: ISDIN
Modality: Recombinant Proteins and Enzymes
Administration: Topical

Overview

**Eryfotona AK-NMSC** is an ISDIN film-forming topical medical device for prevention and adjunctive management of actinic keratosis and non-melanoma skin cancer-associated cutaneous cancerization fields. It combines high UVA/UVB photoprotection with DNA Repairsomes, comprising liposome-encapsulated photolyase, a light-activated DNA-repair enzyme that recognizes and repairs ultraviolet-induced cyclobutane pyrimidine dimers in skin-cell DNA. The product is supplied in cream and fluid formulations for topical application and has been evaluated in clinical studies, including a registered randomized study in patients with actinic keratosis. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01656226))

Brand names: Eryfotona AK-NMSC

Beyond the preview

Go deeper on Eryfotona AK-NMSC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eryfotona AK-NMSC.

Explore the full profile